{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:39:24Z","timestamp":1790735964048,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clml.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T06:50:10Z","timestamp":1681973410000},"page":"610-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-3435","authenticated-orcid":false,"given":"Chia-Yu","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan Sun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalis","family":"Mustafayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-283X","authenticated-orcid":false,"given":"Fareed","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-604X","authenticated-orcid":false,"given":"Harrys A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.04.006_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982346","article-title":"Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy","volume":"13","author":"Ni","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.006_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.clml.2023.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","article-title":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study","volume":"107","author":"Innocenti","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2023.04.006_bib0005","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3026(18)30152-2","article-title":"Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review","volume":"5","author":"Lu","year":"2018","journal-title":"Lancet Haematol"},{"issue":"31","key":"10.1016\/j.clml.2023.04.006_bib0006","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B Virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clml.2023.04.006_bib0008","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.clml.2019.12.006","article-title":"Hepatitis B virus-associated liver failure in a patient with B-cell non-Hodgkin lymphoma after anti-cancer therapy including ibrutinib","volume":"20","author":"Malek","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.clml.2023.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.04.006_bib0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.04.006_bib0012","first-page":"1","article-title":"Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule","author":"Sim","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.clml.2023.04.006_bib0013","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:57Z","timestamp":1761871317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2152265023001350"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}